US20120189707A1 - Production Method For Cryopreserved Acellular Dermal Matrix, And Cryopreserved Acellular Dermal Matrix Produced Thereby - Google Patents

Production Method For Cryopreserved Acellular Dermal Matrix, And Cryopreserved Acellular Dermal Matrix Produced Thereby Download PDF

Info

Publication number
US20120189707A1
US20120189707A1 US13/392,596 US201013392596A US2012189707A1 US 20120189707 A1 US20120189707 A1 US 20120189707A1 US 201013392596 A US201013392596 A US 201013392596A US 2012189707 A1 US2012189707 A1 US 2012189707A1
Authority
US
United States
Prior art keywords
dermal matrix
acellular dermal
skin
cryopreserved
cryoprotectant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/392,596
Inventor
Wook Chun
Weon Ik CHOI
Man Seong Park
Geun Hyung Kim
Jae Deuk Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Hallym University
Original Assignee
Industry Academic Cooperation Foundation of Hallym University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Hallym University filed Critical Industry Academic Cooperation Foundation of Hallym University
Assigned to INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY reassignment INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, WEON IK, CHUN, WOOK, JUNG, JAE DEUK, KIM, GEUN HYUNG, PARK, MAN SEONG
Publication of US20120189707A1 publication Critical patent/US20120189707A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • the present invention relates to a method for preparing a cryopreserved acellular dermal matrix and a cryopreserved acellular dermal matrix prepared therefrom. More specifically, the present invention relates to a method in which a cryoprotectant is prepared by adding sucrose to basic constituents comprising glycerol and a basic solution, and then the resulting solution is used to subject skin tissue in which epidermis and cells in dermis are removed to a cryopreservation process and a cryopreserved acellular dermal matrix prepared therefrom.
  • Skin is the largest organ, covering the entire human body, and has functions of preventing loss of body fluid, influx of toxic substances and microbes from the outside, and protecting the body from physical and chemical stimuli.
  • a protective membrane is needed to prevent infection of impaired regions and the loss of body fluid, along with not leaving a scar at the impaired region and preventing serious shrinkage accompanied by the process of spontaneous cure.
  • impaired skin tissue there are three methods of autograft in which a patient's own skin is transplanted, allograft in which the skin of another human being is transplanted and xenograft in which the skin of an animal is transplanted.
  • autograft is the most ideal. However, when burnt areas are extensive, there is a limitation in the region from which skin tissue may be obtained, and the harvesting region can leave a new scar. Allograft plays a greater role in helping the movement of cells at the periphery of the impaired region and curing than permanent engraftment.
  • An acellular dermis in which the epidermis and cells in the dermis are removed from skin harvested from a corpse to avoid immunorejection is usually used after freezing, for the convenience of storage.
  • collagen tissue in the acellular dermis is destroyed in the course of freezing, the acellular dermis matrix may be rapidly degraded after transplantation.
  • the technical problem to be solved in the present invention is the provision of a new method for preparing a cryopreserved acellular dermal matrix which can efficiently increase stability of tissue and maintain extracellular matrix structure without impairment as compared with the conventional methods, when skin tissue for transplantation is processed.
  • the present invention provides a method for preparing a cryopreserved acellular dermal matrix comprising:
  • the present invention also provides an autograft substitute comprising a cryopreserved acellular dermal matrix which is prepared by the above method.
  • epidermis and cells in dermis of allograft skin are removed to avoid immunorejection.
  • the removal of epidermis and cells in dermis may be carried out according to various methods known in the art, and there is no special limitation thereto.
  • the removal of epidermis may be carried out, for example, by treatment with enzymes such as trypsin, collagenase or dispase, or NaCl solution.
  • the removal of cells in dermis may be carried out, for example, by treatment with Triton X100, Tween 20, Tween 40, Tween 60, Tween 80, SDS (sodium dodecylsulfate) and the like.
  • the basic solution refers to a solution which acts as a base for the preparation of the cryoprotectant, and a buffer solution which is used in treating animal cells or an animal cell culture medium may be used.
  • the buffer solution which is used in the treatment of animal cells—may be used without specific limitation.
  • the example of the buffer solution includes, but is not limited to, PBS (phosphate buffered saline), TBS (Tris-buffered saline), citric acid buffer and the like.
  • the animal cell culture medium used may be any medium known in the art.
  • the example of the animal cell culture medium includes, but is not limited to, MEM (Minimum Essential Media), DMEM (Dulbecco's Modified Eagle Media), RPMI 1640, IMDM (Iscove's Modified Dulbecco's Media), Defined Keratinocyte-SFM (without BPE), Keratinocyte-SFN (with BPE), KnockOut D-MEM, AmnioMAX-II Complete Medium, AmnioMAX-C100 Complete Medium.
  • glycerol and the basic solution may be preferably used in a mixing ratio of 0.5 ⁇ 3.5:9, more preferably 0.8 ⁇ 2:9, most preferably 1:9, based on weight.
  • the mixing ratio of glycerol is less than 0.5, there may be a problem of freezing damage in a freezing step. If the mixing ratio of glycerol is greater than 3.5, there may be a problem of the denaturation of tissue after freezing.
  • a cryoprotectant is prepared by dissolving sucrose in the solution in which glycerol and the basic solution are mixed to the final concentration of 20 to 40% by weight.
  • sucrose when sucrose is added to the cryoprotectant, it plays a role in stabilizing and protecting cell membranes and cell membrane proteins from ice crystals formed in a freezing step.
  • the stability of tissue of the cryopreserved acellular dermal matrix prepared according to the present invention can be improved.
  • the optimal mixing ratio of glycerol, the basic solution and sucrose can further improve the stability of the dermal tissue and maintain the structure of extracellular matrix without impairment.
  • the cryoprotectant is preferably prepared by dissolving sucrose in the basic constituents-mixed solution to the final concentration of 25 to 35% by weight and most preferably 30% by weight.
  • the penetration of the cryoprotectant into skin tissue may be carried out according to conventional methods known in the art.
  • the cryoprotectant may be penetrated into the skin tissue in a low-temperature bath. Time needed for penetration may vary depending on the size of skin tissue and other factors.
  • the cryoprotectant may be penetrated into the skin tissue in a 4° C. low-temperature bath for about 6 to 24 hours.
  • the cryoprotectant-penetrated skin is frozen by using a controlled rate freezer.
  • Use of the controlled rate freezer allows the skin tissue to be frozen at a desired rate.
  • the freezing rate of skin with the controlled rate freezer is preferably ⁇ 0.1° C. to ⁇ 7° C. per minute, more preferably ⁇ 0.5° C. to ⁇ 5° C., still more preferably ⁇ 0.8° C. to ⁇ 3° C., and most preferably ⁇ 1° C. per minute. In the present invention, if the freezing rate is less than ⁇ 0.1° C., the skin tissue freezes too slowly.
  • the tissue may be destroyed by the formation of large ice crystals at the exterior of the tissue since more solute inside of the tissue than outside causes a lowering of the freezing rate inside of the tissue.
  • the temperature of cryoprotectant-penetrated skin is different from the chamber temperature of the controlled rate freezer.
  • the skin tissue may be damaged by the formation of ice crystals.
  • cryopreserved acellular dermal matrix prepared according to the present invention can be efficiently used as a substitute for autograft since the stability of the tissue is high, and extracellular matrix and basement membrane are well maintained without impairment.
  • FIG. 1 is scanning electron microscope photographs of acellular dermal matrixes of Example and Comparative Example with 60 ⁇ and 150 ⁇ magnifications.
  • A Comparative Example, 60 ⁇ ; B: Comparative Example, 150 ⁇ ; C: Example, 60 ⁇ ; D: Example, 150 ⁇ ).
  • FIG. 2 is optical microscope photographs of acellular dermal matrixes of Example and Comparative Example with 100 ⁇ and 200 ⁇ magnifications.
  • FIG. 3 is a graph representing results of degradability measured by the treatment of cryopreserved acellular dermal matrixes which are processed with cryoprotectants comprising sucrose in the final concentration of 10, 15, 20, 25, 30, 35 and 40% by weight with collagenase.
  • P.C. positive control
  • N.C. negative control
  • D.W. distilled water
  • pig skin which is the closest to human skin—is used for preparing ten (10) of both cryopreserved skins and glycerol-preserved skins according to the following methods of Example and Comparative Example.
  • Cryopreserved skin was prepared with pig skin according to the following steps.
  • step (10) Sucrose (Sigma, USA) was added to the solution of step (10) as the final concentration of 30% by weight and dissolved to obtain a cryoprotectant.
  • a low-temperature bath (P-039, CoreTech, Korea) was set at 4° C.
  • step (9) The pig skin of step (9) was put in the 4° C. low-temperature bath, and then the cryoprotectant was penetrated into the pig skin for 12 hours.
  • a controlled rate freezer (14S-A, SY Lab, USA) was prepared.
  • the polyamide bag of step (14) was put in the controlled rate freezer and frozen to ⁇ 150° C. at the rate of ⁇ 1° C. per minute.
  • a freeze-dried skin was prepared with pig skin according to the following steps.
  • a low-temperature bath (P-039, CoreTech, Korea) was set at 4° C.
  • step (9) The pig skin of step (9) was put in the 4° C. low temperature bath, and then the cryoprotectant was penetrated into the pig skin for 12 hours.
  • a freezing dryer (Genesis 25XL, VirTis, USA) was prepared.
  • the Tyvek bag of step (13) was put in the freezing dryer and frozen to ⁇ 70° C. at the rate of ⁇ 1° C. per minute, and then dried under the vacuum of 5 torr for 24 hours to obtain a freeze-dried acellular dermis matrix.
  • freeze-dried acellular dermis matrix was sterilized in an E.O. gas sterilizer (HS-4313EO, HanShin Medical Co., Ltd., Korea).
  • the pig skins prepared according to the above Example and Comparative Example were stained with H & E (hematoxylin & eosin) as follows:
  • a paraffin block was cut with 4 ⁇ m thickness and dried to obtain a paraffin section.
  • a specimen was pre-fixed with 2.5% glutaraldehyde solution (fixative solution) for 2 hours, washed with 0.1M phosphate buffered saline and post-fixed with 1% OsO 4 solution.
  • FIGS. 1 and 2 The optical microscope photographs and scanning electron microscope photographs of the skins of Example and Comparative Example are represented in FIGS. 1 and 2 .
  • Example shows excellent structural stability of collagen—which consists of dermis in the tissue, compared with Comparative Example.
  • Example the destruction of tissue at a freezing step is remarkably reduced as compared with Comparative Example.
  • the processing method of the present invention provides high stability of tissue compared with the conventional freeze-drying method.
  • an acellular dermal matrix according to the present processing method can increase the success rate of grafting and curtail the treatment duration.
  • step (2) The sample of step (2) was treated with ninhydrin color reagent and then absorbance at 570 nm was measured.
  • the above calculated L-leucine release amount is represented in FIG. 3 .
  • a cryopreserved acellular dermal matrix which is processed with a cryoprotectant comprising 20 to 40% by weight of sucrose in the final concentration—shows high stability of tissue so that degradation rate by collagenase is remarkably reduced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Dentistry (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a production method for cryopreserved acellular dermal matrix and to cryopreserved acellular dermal matrix produced thereby, and more specifically it relates to a method in which a cryopreservation agent is made by adding sucrose to basic components consisting of glycerol and a basic solution and in which the resulting solution is used in the cryopreservation of skin tissue from which the cells in the epidermis and dermis have been removed, and relates to cryopreserved acellular dermal matrix produced thereby.

Description

    TECHNICAL FIELD
  • The present invention relates to a method for preparing a cryopreserved acellular dermal matrix and a cryopreserved acellular dermal matrix prepared therefrom. More specifically, the present invention relates to a method in which a cryoprotectant is prepared by adding sucrose to basic constituents comprising glycerol and a basic solution, and then the resulting solution is used to subject skin tissue in which epidermis and cells in dermis are removed to a cryopreservation process and a cryopreserved acellular dermal matrix prepared therefrom.
    • BACKGROUND ART
  • Skin is the largest organ, covering the entire human body, and has functions of preventing loss of body fluid, influx of toxic substances and microbes from the outside, and protecting the body from physical and chemical stimuli. In the case of a patient whose skin is seriously impaired by severe burns, injury, carcinoma excision, skin diseases and the like, a protective membrane is needed to prevent infection of impaired regions and the loss of body fluid, along with not leaving a scar at the impaired region and preventing serious shrinkage accompanied by the process of spontaneous cure. For regenerating impaired skin tissue, there are three methods of autograft in which a patient's own skin is transplanted, allograft in which the skin of another human being is transplanted and xenograft in which the skin of an animal is transplanted. Among them, autograft is the most ideal. However, when burnt areas are extensive, there is a limitation in the region from which skin tissue may be obtained, and the harvesting region can leave a new scar. Allograft plays a greater role in helping the movement of cells at the periphery of the impaired region and curing than permanent engraftment.
  • Specifically, in the case of a third-degree burn in which epidermis, dermis and subcutaneous layers are impaired, skin grafting is essentially required. At present, autograft is the most often used as skin grafting. However, harvesting autograft tissue creates a new injury, increasing patient's pain, time for complete recovery can be extended, and the economic burden is greater. In addition, when insufficient healthy regions remain—as with a severely burned patient—autograft cannot be applied or grafting operations should be performed repeatedly. To resolve the above problems, allograft using the skin of another person and xenograft using the skin of an animal such as a pig have been tried. However, other side effects as well as immunorejection often result.
  • In the case of burn surgeries which are most generally performed in domestic and foreign hospitals, the dead epidermis and dermis layers are removed and skin grafting is then carried out by using an acellular dermis in which the epidermis and cells in the dermis are removed from skin harvested from a corpse to avoid immunorejection. Cultured keratinocytes will then complete the entire skin thereon. Because such a completed skin includes basement membrane, it can play a role in protecting the body from external hazardous substances. However, such a skin graft is very expensive and has a problem in balancing supply and demand since most skin grafts are imported. An acellular dermis in which the epidermis and cells in the dermis are removed from skin harvested from a corpse to avoid immunorejection is usually used after freezing, for the convenience of storage. However, because collagen tissue in the acellular dermis is destroyed in the course of freezing, the acellular dermis matrix may be rapidly degraded after transplantation.
    • DETAILED DESCRIPTION OF THE INVENTION Technical Problem
  • Therefore, the technical problem to be solved in the present invention is the provision of a new method for preparing a cryopreserved acellular dermal matrix which can efficiently increase stability of tissue and maintain extracellular matrix structure without impairment as compared with the conventional methods, when skin tissue for transplantation is processed.
    • Solution to the Problem
  • To solve the above problems, the present invention provides a method for preparing a cryopreserved acellular dermal matrix comprising:
  • i) removing epidermis of allograft skin;
  • ii) removing cells in dermis;
  • iii) mixing glycerol, and a basic solution selected from a buffer solution and an animal cell culture medium;
  • iv) dissolving sucrose in the solution to a final concentration of 20 to 40% by weight to obtain a cryoprotectant;
  • v) penetrating the cryoprotectant into the skin from which epidermis and cells in dermis are removed; and
  • vi) freezing the cryoprotectant-penetrated skin in a controlled rate freezer.
  • The present invention also provides an autograft substitute comprising a cryopreserved acellular dermal matrix which is prepared by the above method.
  • Hereinafter, the present invention is described in detail.
  • In the present invention, epidermis and cells in dermis of allograft skin are removed to avoid immunorejection. The removal of epidermis and cells in dermis may be carried out according to various methods known in the art, and there is no special limitation thereto. The removal of epidermis may be carried out, for example, by treatment with enzymes such as trypsin, collagenase or dispase, or NaCl solution. The removal of cells in dermis may be carried out, for example, by treatment with Triton X100, Tween 20, Tween 40, Tween 60, Tween 80, SDS (sodium dodecylsulfate) and the like.
  • In the present invention, glycerol and a basic solution are used as basic constituents of a cryoprotectant. In the present invention, the basic solution refers to a solution which acts as a base for the preparation of the cryoprotectant, and a buffer solution which is used in treating animal cells or an animal cell culture medium may be used. In the present invention, the buffer solution—which is used in the treatment of animal cells—may be used without specific limitation. The example of the buffer solution includes, but is not limited to, PBS (phosphate buffered saline), TBS (Tris-buffered saline), citric acid buffer and the like. In the present invention, the animal cell culture medium used may be any medium known in the art. In the present invention, the example of the animal cell culture medium includes, but is not limited to, MEM (Minimum Essential Media), DMEM (Dulbecco's Modified Eagle Media), RPMI 1640, IMDM (Iscove's Modified Dulbecco's Media), Defined Keratinocyte-SFM (without BPE), Keratinocyte-SFN (with BPE), KnockOut D-MEM, AmnioMAX-II Complete Medium, AmnioMAX-C100 Complete Medium. In the present invention, glycerol and the basic solution may be preferably used in a mixing ratio of 0.5˜3.5:9, more preferably 0.8˜2:9, most preferably 1:9, based on weight. In the present invention, if the mixing ratio of glycerol is less than 0.5, there may be a problem of freezing damage in a freezing step. If the mixing ratio of glycerol is greater than 3.5, there may be a problem of the denaturation of tissue after freezing.
  • In the present invention, a cryoprotectant is prepared by dissolving sucrose in the solution in which glycerol and the basic solution are mixed to the final concentration of 20 to 40% by weight. In the present invention, when sucrose is added to the cryoprotectant, it plays a role in stabilizing and protecting cell membranes and cell membrane proteins from ice crystals formed in a freezing step. As a result, the stability of tissue of the cryopreserved acellular dermal matrix prepared according to the present invention can be improved. In addition, the optimal mixing ratio of glycerol, the basic solution and sucrose can further improve the stability of the dermal tissue and maintain the structure of extracellular matrix without impairment. In the present invention, if the concentration of sucrose is less than 20% by weight, the stability of the tissue may be decreased due to ice crystals formed in a freezing step. If the concentration of sucrose is greater than 40% by weight, the stability of the tissue may be deteriorated by sugar crystals formed in the tissue after freeze-drying due to high concentration of sugar ingredients. In the present invention, the cryoprotectant is preferably prepared by dissolving sucrose in the basic constituents-mixed solution to the final concentration of 25 to 35% by weight and most preferably 30% by weight.
  • In the present invention, the penetration of the cryoprotectant into skin tissue may be carried out according to conventional methods known in the art. Preferably, the cryoprotectant may be penetrated into the skin tissue in a low-temperature bath. Time needed for penetration may vary depending on the size of skin tissue and other factors. For example, the cryoprotectant may be penetrated into the skin tissue in a 4° C. low-temperature bath for about 6 to 24 hours.
  • In the present invention, the cryoprotectant-penetrated skin is frozen by using a controlled rate freezer. Use of the controlled rate freezer allows the skin tissue to be frozen at a desired rate. In the present invention, the freezing rate of skin with the controlled rate freezer is preferably −0.1° C. to −7° C. per minute, more preferably −0.5° C. to −5° C., still more preferably −0.8° C. to −3° C., and most preferably −1° C. per minute. In the present invention, if the freezing rate is less than −0.1° C., the skin tissue freezes too slowly. As a result, the tissue may be destroyed by the formation of large ice crystals at the exterior of the tissue since more solute inside of the tissue than outside causes a lowering of the freezing rate inside of the tissue. In addition, when the skin tissue is frozen, the temperature of cryoprotectant-penetrated skin is different from the chamber temperature of the controlled rate freezer. As a result, if latent heat of fusion is not controlled by an excessive freezing rate of −7° C. per minute due to rapid freezing from the region in which latent heat of fusion is generated at freezing to −80° C. which is the temperature where the movement of water molecules stops, the skin tissue may be damaged by the formation of ice crystals.
    • Effects of the Invention
  • The cryopreserved acellular dermal matrix prepared according to the present invention can be efficiently used as a substitute for autograft since the stability of the tissue is high, and extracellular matrix and basement membrane are well maintained without impairment.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is scanning electron microscope photographs of acellular dermal matrixes of Example and Comparative Example with 60× and 150× magnifications. (A: Comparative Example, 60×; B: Comparative Example, 150×; C: Example, 60×; D: Example, 150×).
  • FIG. 2 is optical microscope photographs of acellular dermal matrixes of Example and Comparative Example with 100× and 200× magnifications. (A: Comparative Example, 100×; B: Comparative Example, 200×; C: Example, 100×; D: Example, 200×).
  • FIG. 3 is a graph representing results of degradability measured by the treatment of cryopreserved acellular dermal matrixes which are processed with cryoprotectants comprising sucrose in the final concentration of 10, 15, 20, 25, 30, 35 and 40% by weight with collagenase. (P.C. (positive control): treatment of collagen powder with collagenase; N.C. (negative control): No treatment of collagenase; D.W.: distilled water).
    •  DESCRIPTION OF EMBODIMENTS
  • The present invention is explained in more detail with the following examples. However, it must be understood that the protection scope of the present invention is not limited to the examples.
  • Because human skin tissue harvested from a donor (cadaver) is prohibited from being used in an experiment, pig skin—which is the closest to human skin—is used for preparing ten (10) of both cryopreserved skins and glycerol-preserved skins according to the following methods of Example and Comparative Example.
    • EXAMPLE
  • Cryopreserved skin was prepared with pig skin according to the following steps.
  • (1) Pig skin was washed with saline solution.
  • (2) The pig skin was cut at the size of 5×10 cm2.
  • (3) The pig skin was immersed in 1M NaCl (Sigma, USA) solution.
  • (4) A 38° C. incubator (P-039, CoreTech, Korea) was prepared.
  • (5) The reaction of the pig skin immersed in 1M NaCl (Sigma, USA) solution was carried out in the 38° C. incubator with stirring for about 6 to 24 hours.
  • (6) Epidermis was removed by using forceps.
  • (7) The dermis from which epidermis has been removed was washed with phosphate buffered saline (pH 7.2, Gibco, USA).
  • (8) The washed dermis was immersed in 0.1% SDS and reacted with stirring at room temperature for 1 hour to remove cells from the dermis.
  • (9) The dermis from which cells have been removed was washed with phosphate buffered saline.
  • (10) Glycerol (Sigma, USA) and phosphate buffered saline were mixed in the weight ratio of 1:9.
  • (11) Sucrose (Sigma, USA) was added to the solution of step (10) as the final concentration of 30% by weight and dissolved to obtain a cryoprotectant.
  • (12) A low-temperature bath (P-039, CoreTech, Korea) was set at 4° C.
  • (13) The pig skin of step (9) was put in the 4° C. low-temperature bath, and then the cryoprotectant was penetrated into the pig skin for 12 hours.
  • (14) The penetration-completed pig skin was put in a polyamide bag (CryoBag™, Origen, USA).
  • (15) A controlled rate freezer (14S-A, SY Lab, USA) was prepared.
  • (16) The polyamide bag of step (14) was put in the controlled rate freezer and frozen to −150° C. at the rate of −1° C. per minute.
  • (17) After freezing, the polyamide bag was kept frozen in a dry shipper until analysis experiments.
    • Comparative Example
  • A freeze-dried skin was prepared with pig skin according to the following steps.
  • (1) Pig skin was washed with saline solution.
  • (2) The pig skin was cut at the size of 5×10 cm2.
  • (3) The pig skin was immersed in 1M NaCl (Sigma, USA) solution.
  • (4) A 38° C. incubator (P-039, CoreTech, Korea) was prepared.
  • (5) The reaction of the pig skin immersed in 1M NaCl (Sigma, USA) solution was carried out in the 38° C. incubator with stirring for about 6 to 24 hours.
  • (6) Epidermis was removed by using forceps.
  • (7) The dermis from which epidermis has been removed was washed with phosphate buffered saline (pH 7.2, Gibco, USA).
  • (8) The washed dermis was immersed in 0.1% SDS and reacted with stirring at room temperature for 1 hour to remove cells from the dermis.
  • (9) The dermis from which cells have been removed was washed with phosphate buffered saline.
  • (10) Glycerol (Sigma, USA) and phosphate buffered saline were mixed in the weight ratio of 1:9 to obtain a cryoprotectant.
  • (11) A low-temperature bath (P-039, CoreTech, Korea) was set at 4° C.
  • (12) The pig skin of step (9) was put in the 4° C. low temperature bath, and then the cryoprotectant was penetrated into the pig skin for 12 hours.
  • (13) The penetration-completed pig skin and 50 ml of the cryoprotectant were put in a Tyvek bag (Korea C & S Co., Ltd., Korea).
  • (14) A freezing dryer (Genesis 25XL, VirTis, USA) was prepared.
  • (15) The Tyvek bag of step (13) was put in the freezing dryer and frozen to −70° C. at the rate of −1° C. per minute, and then dried under the vacuum of 5 torr for 24 hours to obtain a freeze-dried acellular dermis matrix.
  • (16) After freeze-drying, the freeze-dried acellular dermis matrix was sterilized in an E.O. gas sterilizer (HS-4313EO, HanShin Medical Co., Ltd., Korea).
  • (17) The sterilized, freeze-dried acellular dermis matrix was sealed in an aluminum bag and stored at room temperature until analysis experiments.
    • Experimental Example 1 Histological Examination
  • The pig skins prepared according to the above Example and Comparative Example were stained with H & E (hematoxylin & eosin) as follows:
  • (1) A paraffin block was cut with 4 μm thickness and dried to obtain a paraffin section.
  • (2) For deparaffinization, after conducting xylene treatment of 5 minutes three times, 100% ethanol treatment of 2 minutes two times, 90% ethanol treatment of 1 minute one time, 80% ethanol treatment of 1 minute one time and 70% ethanol treatment of 1 minute one time, the section was rinsed in running water for 10 minutes.
  • (3) After staining with hematoxylin for 10 minutes, the section was rinsed in running water for 3 minutes. Then, after staining with eosin for 10 minutes, the section was rinsed in running water until no eosin was detected in the rinse water. After conducting 70% ethanol treatment of 1 second ten times, 80% ethanol treatment of 1 second ten times, 90% ethanol treatment of 1 second ten times, 100% ethanol treatment of 1 minute two times and xylene treatment of 3 minutes three times, the section was mounted with a mounting solution.
  • The scanning electron microscope observation of the pig skins prepared according to the above Example and Comparative Example was carried out as follows:
  • (1) A specimen was pre-fixed with 2.5% glutaraldehyde solution (fixative solution) for 2 hours, washed with 0.1M phosphate buffered saline and post-fixed with 1% OsO4 solution.
  • (2) The fixed specimen was hydrated and substituted through a series of increased ethanol concentration, and then the specimen was frozen and fractured in −190° C. liquid nitrogen to expose the cross section, and completely dried by using a critical point dryer (HCP-2).
  • (3) The specimen was fixed at an aluminum stub (specimen mount) with the fractured surface upward, and metal coated with Pt—Pd at about 10 mm thickness by using a metal ion coating system (E-1030 ion sputter).
  • (4) The specimen was observed and photographed with a scanning electron microscope (Hitachi S-4700, Japan).
  • The optical microscope photographs and scanning electron microscope photographs of the skins of Example and Comparative Example are represented in FIGS. 1 and 2.
  • From the results of FIGS. 1 and 2, it can be known that Example shows excellent structural stability of collagen—which consists of dermis in the tissue, compared with Comparative Example.
  • In addition, from the microscope photographs of FIGS. 1 and 2, it can be known that in Example the destruction of tissue at a freezing step is remarkably reduced as compared with Comparative Example.
  • That is, the processing method of the present invention provides high stability of tissue compared with the conventional freeze-drying method. As a result, an acellular dermal matrix according to the present processing method can increase the success rate of grafting and curtail the treatment duration.
    • Experimental Example 2 Measurement of Degradability by Collagenase
  • To evaluate the stability of acellular dermal matrix according to the concentration of sucrose, the degradability by collagenase was measured as follows:
  • (1) 25 mg of sample was added to 5 mM TES buffer containing 0.36 mM calcium chloride and mixed well.
  • (2) 0.1 ml of collagenase (0.1 mg/ml) was added to the sample of step (1) and incubated at 37° C. for one day with stirring.
  • (3) 4.0 mM L-leucine standard solution was serially diluted and treated with ninhydrin color reagent. A standard curve was prepared by measuring absorbance at 570 nm (VERSA max, Molecular Device, USA).
  • (4) The sample of step (2) was treated with ninhydrin color reagent and then absorbance at 570 nm was measured.
  • (5) The amount of released L-leucine from each sample was calculated by using the L-leucine standard curve of step (3).
  • The above calculated L-leucine release amount is represented in FIG. 3. As can be seen from FIG. 3, a cryopreserved acellular dermal matrix—which is processed with a cryoprotectant comprising 20 to 40% by weight of sucrose in the final concentration—shows high stability of tissue so that degradation rate by collagenase is remarkably reduced.

Claims (8)

1. A method for preparing a cryopreserved acellular dermal matrix comprising:
i) removing epidermis of allograft skin;
ii) removing cells in dermis;
iii) mixing glycerol, and a basic solution selected from a buffer solution and an animal cell culture medium;
iv) dissolving sucrose in the solution to a final concentration of 20 to 40% by weight to obtain a cryoprotectant;
v) penetrating the cryoprotectant into the skin from which epidermis and cells in dermis are removed; and
vi) freezing the cryoprotectant-penetrated skin in a controlled rate freezer.
2. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the mixing ratio of glycerol and the basic solution is 0.5˜3:9 based on weight.
3. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the buffer solution is selected from PBS (phosphate buffered saline), TBS (Tris-buffered saline) and citric acid buffer.
4. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the animal cell culture medium is selected from MEM (Minimum Essential Media), DMEM (Dulbecco's Modified Eagle Media), RPMI 1640, IMDM (Iscove's Modified Dulbecco's Media), Defined Keratinocyte-SFM (without BPE), Keratinocyte-SFN (with BPE), KnockOut D-MEM, AmnioMAX-II Complete Medium and AmnioMAX-C100 Complete Medium.
5. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the final concentration of sucrose is 30% by weight.
6. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the cryoprotectant is penetrated into the separated skin in a 4° C. low-temperature bath for 6 to 24 hours.
7. The method for preparing a cryopreserved acellular dermal matrix according to claim 1, wherein the cryoprotectant-penetrated skin is frozen in a controlled rate freezer at a freezing rate of −1° C. per minute.
8. An autograft substitute comprising the cryopreserved acellular dermal matrix which is prepared by the method according to any one of claims 1 to 7.
US13/392,596 2009-09-11 2010-09-09 Production Method For Cryopreserved Acellular Dermal Matrix, And Cryopreserved Acellular Dermal Matrix Produced Thereby Abandoned US20120189707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020090085666A KR101107022B1 (en) 2009-09-11 2009-09-11 Methods for preparing cryopreserved acellular dermal substrates and cryopreserved acellular dermal substrates prepared therefrom
KR10-2009-0085666 2009-09-11
PCT/KR2010/006146 WO2011031077A2 (en) 2009-09-11 2010-09-09 Production method for cryopreserved acellular dermal matrix, and cryopreserved acellular dermal matrix produced thereby

Publications (1)

Publication Number Publication Date
US20120189707A1 true US20120189707A1 (en) 2012-07-26

Family

ID=43732955

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/392,596 Abandoned US20120189707A1 (en) 2009-09-11 2010-09-09 Production Method For Cryopreserved Acellular Dermal Matrix, And Cryopreserved Acellular Dermal Matrix Produced Thereby

Country Status (4)

Country Link
US (1) US20120189707A1 (en)
KR (1) KR101107022B1 (en)
CN (1) CN102573945B (en)
WO (1) WO2011031077A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289452B2 (en) 2013-03-07 2016-03-22 Allosource Consistent calcium content bone allograft systems and methods
US9808558B2 (en) 2008-11-20 2017-11-07 Allosource Allografts combined with tissue derived stem cells for bone healing
WO2020039397A1 (en) * 2018-08-24 2020-02-27 Xenogp Sp. Z O. O. Method for obtaining a pig skin dressing and the medical use of a pig skin dressing
US10675016B2 (en) 2015-10-30 2020-06-09 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US10702260B2 (en) 2016-02-01 2020-07-07 Medos International Sàrl Soft tissue fixation repair methods using tissue augmentation scaffolds
US11484401B2 (en) 2016-02-01 2022-11-01 Medos International Sarl Tissue augmentation scaffolds for use in soft tissue fixation repair
US12376843B2 (en) 2016-02-01 2025-08-05 Medos International Sàrl Tissue augmentation tacks for use with soft tissue fixation repair systems and methods

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101362402B1 (en) * 2012-03-15 2014-02-14 김준용 Acellular dermal matrix removed basement membrane
KR102040592B1 (en) * 2013-03-18 2019-11-06 주식회사 엘앤씨바이오 Method of manufacturing implantation materials
CN103285420B (en) * 2013-03-28 2015-03-25 北京桀亚莱福生物技术有限责任公司 A kind of preparation method of human biological dressing for covering burn wound wound surface
CN103990179B (en) * 2014-05-24 2017-08-29 河北爱能生物科技股份有限公司 A kind of method for preparing xenogenesis acellular matrix and products thereof
CN106310384A (en) * 2015-07-01 2017-01-11 江西瑞诺健医学科技有限公司 Xenogeneic acellular dermis and preparation method thereof
CN105833353B (en) * 2016-05-09 2018-04-20 拜欧迪赛尔（北京）生物科技有限公司 A kind of preparation of bioengineering acellular dermal matrix and purposes
CN105833356B (en) * 2016-05-09 2018-02-16 拜欧迪赛尔（北京）生物科技有限公司 A kind of new de- cell Valved allograft support and preparation method thereof
CN105944142B (en) * 2016-05-09 2018-07-13 拜欧迪赛尔（北京）生物科技有限公司 A kind of preparation method of de- cell tendon or tough belt supporting frame
CN105879118B (en) * 2016-05-09 2018-03-02 拜欧迪赛尔（北京）生物科技有限公司 A kind of bioengineering takes off the preparation method of cellular cartilage
CN111982629B (en) * 2020-08-25 2023-11-17 北京市农林科学院 A method for ultrathin frozen sectioning of edible fungus tissue cells
WO2022131407A1 (en) * 2020-12-18 2022-06-23 주식회사 엘앤씨바이오 Dermis-based artificial skin comprising basement membrane layer and manufacturing method therefor
KR20250082872A (en) 2023-11-30 2025-06-09 주식회사 퍼즐비 Composition for producing acellular dermal matrix and method for producing acellular dermal matrix using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US6740484B1 (en) * 1999-04-13 2004-05-25 Organ Recovery Systems, Inc. Method of cryopreservation of tissues by vitrification
US20060210960A1 (en) * 1990-09-12 2006-09-21 Lifecell Corporation, A Texas Corporation Method for processing and preserving collagen-based tissues for transplantation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000181A1 (en) * 1988-10-14 1990-04-14 Chung-Faye Chao Process for producing cultured epidermal sheet, product and method of use
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US8394371B2 (en) * 2002-02-11 2013-03-12 Neocutis Sa Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
KR100688443B1 (en) * 2005-03-11 2007-03-02 경상남도 Serum-free cryopreservation solution for long-term storage of cellular artificial tissue and cryopreservation method of cellular artificial tissue using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210960A1 (en) * 1990-09-12 2006-09-21 Lifecell Corporation, A Texas Corporation Method for processing and preserving collagen-based tissues for transplantation
US6740484B1 (en) * 1999-04-13 2004-05-25 Organ Recovery Systems, Inc. Method of cryopreservation of tissues by vitrification
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
McCarthy et al, Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy, 1995, NEUROLOGY, 45: 1848-1855 *
Reagan et al., Analysis of Cellular and Decellular Allogeneic Dermal Grafts for the Treatment of Full-Thickness Wounds in a Porcine Model, 1997, The Journal of Trauma: Injury, Infection, and Critical Care 43(3): 458-466 *
Wang et al, The Cryopreservation of a Tissue Engineered Dermal Replacement by Programmed Freezing 2005, Proceedings of the 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference, pages 494 - 497 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808558B2 (en) 2008-11-20 2017-11-07 Allosource Allografts combined with tissue derived stem cells for bone healing
US9814803B2 (en) 2008-11-20 2017-11-14 Allosource Allografts combined with tissue derived stem cells for bone healing
US9486556B2 (en) 2013-03-07 2016-11-08 Allosource Consistent calcium content bone allograft systems and methods
US9289452B2 (en) 2013-03-07 2016-03-22 Allosource Consistent calcium content bone allograft systems and methods
US11375996B2 (en) 2015-10-30 2022-07-05 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US12150642B2 (en) 2015-10-30 2024-11-26 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US10675016B2 (en) 2015-10-30 2020-06-09 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US10765423B2 (en) 2015-10-30 2020-09-08 New York Society For The Relief Of The Ruptured And Crippled, Maintaing The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US10835235B2 (en) 2015-10-30 2020-11-17 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US11426156B2 (en) 2015-10-30 2022-08-30 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Suture sleeve patch and methods of delivery within an existing arthroscopic workflow
US11484401B2 (en) 2016-02-01 2022-11-01 Medos International Sarl Tissue augmentation scaffolds for use in soft tissue fixation repair
US11357495B2 (en) 2016-02-01 2022-06-14 Medos International Sarl Tissue augmentation scaffolds for use with soft tissue fixation repair systems and methods
US10702260B2 (en) 2016-02-01 2020-07-07 Medos International Sàrl Soft tissue fixation repair methods using tissue augmentation scaffolds
US11523812B2 (en) 2016-02-01 2022-12-13 Medos International Sarl Soft tissue fixation repair methods using tissue augmentation constructs
US11938017B2 (en) 2016-02-01 2024-03-26 Medos International Srl Tissue augmentation scaffolds for use in soft tissue fixation repair
US11937803B2 (en) 2016-02-01 2024-03-26 Medos International Sarl Soft tissue fixation repair methods using tissue augmentation constructs
US12376843B2 (en) 2016-02-01 2025-08-05 Medos International Sàrl Tissue augmentation tacks for use with soft tissue fixation repair systems and methods
WO2020039397A1 (en) * 2018-08-24 2020-02-27 Xenogp Sp. Z O. O. Method for obtaining a pig skin dressing and the medical use of a pig skin dressing

Also Published As

Publication number Publication date
KR101107022B1 (en) 2012-01-25
KR20110027880A (en) 2011-03-17
WO2011031077A2 (en) 2011-03-17
WO2011031077A3 (en) 2011-07-14
CN102573945B (en) 2015-03-25
CN102573945A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
US20120189707A1 (en) Production Method For Cryopreserved Acellular Dermal Matrix, And Cryopreserved Acellular Dermal Matrix Produced Thereby
US9623149B2 (en) Method for producing an acellular dermal matrix, and acellular dermal matrix produced by same
DE69333926T2 (en) Method for processing and preserving collagen-based tissue parts for transplantation
DE60007304T2 (en) METHOD FOR CRYOPRESERVATING BLOOD VESSELS THROUGH GLASS FORMATION
CN1245222C (en) Method for preparing cis dehydrated tissue for implantation
RU2478403C2 (en) Sterile autologous, allogenic or xenogenic implants and method for making it
Kajbafzadeh et al. Whole organ sheep kidney tissue engineering and in vivo transplantation: effects of perfusion-based decellularization on vascular integrity
Boren et al. Maintenance of viable arterial allografts by cryopreservation
US20070269791A1 (en) Method of Preparing Isolated Cell-Free Skin, Cell-Free Dermal Matrix, Method of Producing the Same and Composite Cultured Skin with The Use of the Cell-Free Dermal Matrix
KR20190036882A (en) Manufacturing method of bio-graft or bio-implant comprising acellular dermal matrix derived from pig
Yang et al. Effect of cryoprotectants on rat kidney decellularization by freeze-thaw process
CN113767895A (en) A kind of hair follicle tissue composite preservation solution, its preparation method and the preservation method of maintaining hair follicle in vitro activity
KR101330646B1 (en) Method for preparing cryo-preserved xenograft skin and cryo-preserved xenograft skin prepared therefrom
US11013228B2 (en) Method of processing allograft skin for transplantation, and cryopreserved allograft skin produced thereby
KR20190036861A (en) A Composition for Cryopreservation of acellular dermal matrix and a Method for making the Same
JP5610268B2 (en) Method for decellularization of biological tissue with hypertonic electrolyte solution
JP2005185507A (en) Separation and non-cellularization method of skin, acellular dermal matrix and its production method, and composite cultivated skin using acellular dermal matrix
CN108094410B (en) A kind of skin deep and low temperature protective agent and skin preservation method
JP2005211480A (en) Method of preparing isolated cell-free skin, cell-free dermal matrix, method of producing the same and composite cultured skin with the use of the cell-free dermal matrix
Morsi et al. The use of close relative allo-graft intermingled with auto-graft for the management of extensive burn injury
Mora et al. Efficient recellularization of human vascular grafts with patient derived endothelial cells
SU1367931A1 (en) Method of preserving tooth rudiment
RU2212792C2 (en) Solution for cryopreservation of skin and cornea
Døssing et al. Freeze-dried and non-freeze-dried split-skin allografts on excised burns
KR20060099312A (en) Serum-free cryopreservation solution for long-term storage of cellular artificial tissue and cryopreservation method of cellular artificial tissue using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM U

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHUN, WOOK;CHOI, WEON IK;PARK, MAN SEONG;AND OTHERS;REEL/FRAME:028042/0115

Effective date: 20111216

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION